Olwen Hahn
Section of Hematology / Oncology
Associate Professor of Medicine
Referring Physician Access Line: 1-877-DOM-2730

Training

DegreeYearInstitutionArea
BA1997Princeton UniversityMolecular Biology
MD2001Emory University, School of MedicineMedicine
Residency2004The University of Chicago Medical CenterInternal Medicine
Fellowship2007The University of Chicago Medical CenterHematology/Oncology

Academic Interests

Dr. Hahn specializes in adult hematology/oncology focusing on the treatment of breast and genitourinary malignancies. She is an Executive Officer for the National Cancer Institute-funded oncology research organization, the Cancer and Leukemia Group B and in this role oversees the development of national clinical trials in breast, respiratory, and genitourinary malignancies.


Clinical Interests

Breast cancer, Renal Cancer, Bladder Cancer, Prostate Cancer, and Testicular Cancer


Representative Publications

  1. Hahn O and Salgia R, Novel Therapies for Lung Cancer, Hematology Oncology Clinics of North America, 2005:19:2:343-368.
  2. Hahn O, Stadler WM. Sorafenib, Curr Opin Oncol. 2006 Nov;18(6):615-21.
  3. Hahn O and Salgia R, Non-Receptor Tyrosine Kinase Inhibitors in Lung Cancer, Current Medicinal Chemistry, Anticancer Agents Med Chem 2007 Nov;7(6):633-42.
  4. O Hahn, C Yang, M Medved, G Karczmar, E Krisner, T Karrison, B Manchen, M Mitchell, M Ratain, W Stadler. Dynamic contrast enhanced MRI: a pharmacodynamic study of sorafenib in metastatic renal cell carcinoma: results of randomized, phase II trial. J Clin Oncol. 2008 Oct 1;26(28):4572-8.



More Information

For more information about Dr. Olwen Hahn publications and research collaborations , please click here